Abstract
Importance Disparities in pulse oximetry accuracy, disproportionately affecting patients of color, have been associated with serious clinical outcomes. Although many have called for pulse oximetry hardware replacement, the cost associated with this replacement is not known.
Objective To estimate the cost of replacing all pulse oximetry hardware throughout a hospital system.
Design Single-center survey, 2023
Setting Single center.
Participant One academic medical center with three hospitals.
Main Outcomes and Measures Cost of fleet replacement as identified by current day prices for hardware.
Results New and used prices for 5,079/5,678 (89.5%) across three hospitals for pulse oximetry devices were found. The average equipment cost to replace pulse oximetry hardware is $15,704.12 per bed. Replacement and integration costs are estimated at $28.5-31.8 million for the entire medical system. Extrapolating these costs to 5,564 hospitals in the United States results in an estimated cost of $14.1 billion.
Conclusions and Relevance “Simply replacing” pulse oximetry hardware to address disparities may be neither simple, cheap, or timely. Solutions for addressing pulse oximetry accuracy disparities leveraging current technology may be necessary.
Trial Registration Pro00113724, exempt
Question What is the cost and complexity of replacing pulse oximetry technology to improve disparities, both at a single institution and across the US?
Findings In this observational study of pulse oximetry devices in an academic medical system with three hospitals, new and used prices were found for 5,079/5,678 devices (89.5%), with fleet replacement and integration cost of $28.5-31.8 million and some life cycles extending beyond 18 years. When extrapolated to 5,564 hospitals in the United States, estimated replacement costs are $9.7-$20.1 billion.
Meaning The monetary and time cost of pulse oximetry hardware replacement is substantial, and solutions utilizing current pulse oximetry technology are essential to delivering equitable care to all patients.
Competing Interest Statement
AIW holds equity and management roles in Ataia Medical. The other authors have no conflicts of interest to disclose.
Funding Statement
AIW is supported by the Duke CTSI by the National Center for Advancing Translational Sciences of the NIH under UL1TR002553 and the National Institute on Minority Health and Health Disparities REACH Equity Award under 5U54MD012530. All others state no conflict of interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Duke University Health System IRB approved Protocol Pro00113724 as exempt.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing interests AIW holds equity and management roles in Ataia Medical.
The other authors have no conflicts of interest to disclose.
Funding AIW is supported by the Duke CTSI by the National Center for Advancing Translational Sciences of the NIH under UL1TR002553 and the National Institute on Minority Health and Health Disparities REACH Equity Award under 5U54MD012530. All others state no conflict of interest.
The other authors have no conflicts of interest to disclose.
Data Availability
We can make percentages available for units above 1% prevalence.
